Patient-Based Therapeutics
AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
Patient Focused
learn about our work
Neurodegenerative Disease Areas
Latest News
PASADENA, Calif., April 16, 2026 – AcuraStem, a patient‑based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced the establishment of its European subsidiary, AcuraStem P2 Ltd, based in Nicosia, Cyprus.
PASADENA, Calif., March 10, 2026 — AcuraStem, a patient-based biotechnology company developing disease- modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ALS to advance therapeutics targeting SYF2, a recently identified regulator of TDP43 function. TDP-43 dysfunction is a central biological hallmark of ALS.
AcuraStem presented new poster data at the 36th International Symposium on ALS/MND, held December 5–7, 2025 in San Diego, USA, at the Loews Coronado Bay Resort. The Symposium, organized by the MND Association, is the largest annual conference dedicated to ALS and MND research and brings together researchers from around the world to share new findings.